作者：
Rosanne,Janssens [1]
;
Liese,Barbier [1]
;
Mireille,Muller [2]
;
Irina,Cleemput [3]
;
Isabelle,Stoeckert [4]
;
Chiara,Whichello [5]
;
Bennett,Levitan [6]
;
Tarek A,Hammad [7]
;
Charis,Girvalaki [8]
;
Juan-Jose,Ventura [8]
;
Karin Schölin,Bywall [9]
;
Cathy Anne,Pinto [10]
;
Elise,Schoefs [11]
;
Eva G,Katz [1]
;
Ulrik,Kihlbom [12]
;
Isabelle,Huys [13]
作者单位：
Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
[1]
Novartis Pharma AG, Basel, Switzerland.
[2]
Belgian Healthcare Knowledge Centre (KCE), Brussels, Belgium.
[3]
Bayer AG, Wuppertal, Germany.
[4]
Evidera, London, United Kingdom.
[5]
Global Epidemiology, Janssen R&D, LLC, Pennsylvania, PA, United States.
[6]
Takeda Pharmaceuticals, Cambridge, MA, United States.
[7]
European Cancer Patient Coalition (ECPC), Brussels, Belgium.
[8]
School of Health, Care and Social Welfare, Division of Health and Welfare Technology, Mälardalen University, Västerås, Sweden.
[9]
Department of Public Health and Caring Sciences, Centre for Research Ethics & Bioethics, Uppsala University, Uppsala, Sweden.
[10]
Merck & Co., Inc., Rahway, NJ, United States.
[11]
Janssen Global Services, LLC, Raritan, NJ, United States.
[12]
Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Solna, Sweden.
[13]
DOI
10.3389/fphar.2023.1192770
PMID
37663265
发布时间
2023-09-05
换一批
换一批
